

Dominika Anna Nowis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8497221/publications.pdf>

Version: 2024-02-01

102
papers

7,766
citations

145106

33
h-index

62345

84
g-index

106
all docs

106
docs citations

106
times ranked

13321
citing authors

#	ARTICLE	IF	CITATIONS
1	Ablation of Tmcc2 Gene Impairs Erythropoiesis in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5263.	1.8	3
2	Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma. <i>Oncology</i> , 2021, 10, 1956143.	2.1	30
3	Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development. <i>Cancers</i> , 2021, 13, 870.	1.7	28
4	Inhibition of the γ -glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors. <i>Cancer Letters</i> , 2021, 507, 13-25.	3.2	20
5	The role of CD71+ erythroid cells in the regulation of the immune response. , 2021, 228, 107927.		37
6	Mosaic <i>IL6ST</i> variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphism. <i>Human Molecular Genetics</i> , 2021, 30, 226-233.	1.4	8
7	Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. <i>Cancer Research</i> , 2021, 81, 6029-6043.	0.4	20
8	MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance. <i>Cell Death and Disease</i> , 2021, 12, 1111.	2.7	12
9	Potent but transient immunosuppression of T-cells is a general feature of CD71+ erythroid cells. <i>Communications Biology</i> , 2021, 4, 1384.	2.0	12
10	Transport of nanoprobe in multicellular spheroids. <i>Nanoscale</i> , 2020, 12, 19880-19887.	2.8	9
11	Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects. <i>Cancers</i> , 2020, 12, 2540.	1.7	36
12	Myeloid Cell-Derived Arginase in Cancer Immune Response. <i>Frontiers in Immunology</i> , 2020, 11, 938.	2.2	249
13	Immunoglobulin expression and the humoral immune response is regulated by the non-canonical poly(A) polymerase TENT5C. <i>Nature Communications</i> , 2020, 11, 2032.	5.8	34
14	The identity and methylation status of the first transcribed nucleotide in eukaryotic mRNA 5' cap modulates protein expression in living cells. <i>Nucleic Acids Research</i> , 2020, 48, 1607-1626.	6.5	76
15	Systematic Evaluation of Chemically Distinct Tissue Optical Clearing Techniques in Murine Lymph Nodes. <i>Journal of Immunology</i> , 2020, 204, 1395-1407.	0.4	10
16	Bone marrow is the preferred site of memory CD4+ T cell proliferation during recovery from sepsis. <i>JCI Insight</i> , 2020, 5, .	2.3	16
17	Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies. <i>Blood</i> , 2020, 136, 33-34.	0.6	0
18	Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. <i>Nature Communications</i> , 2019, 10, 3000.	5.8	194

#	ARTICLE	IF	CITATIONS
19	Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells. <i>Oncogene</i> , 2019, 38, 2860-2875.	2.6	19
20	Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer. <i>Annals of Agricultural and Environmental Medicine</i> , 2019, 26, 415-419.	0.5	12
21	Peroxiredoxin-5 is a negative survival predictor in ovarian cancer. <i>Ginekologia Polska</i> , 2019, 90, 1-6.	0.3	7
22	STING Signaling in Cancer Cells: Important or Not?. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 125-132.	1.0	56
23	Evidence of ER stress and UPR activation in patients with Brody disease and Brody syndrome. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 533-536.	1.8	1
24	Neurodevelopmental phenotype caused by a de novo <i>PTPN4</i> single nucleotide variant disrupting protein localization in neuronal dendritic spines. <i>Clinical Genetics</i> , 2018, 94, 581-585.	1.0	13
25	Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. <i>Haematologica</i> , 2018, 103, 1843-1852.	1.7	8
26	Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002505.	3.9	31
27	Bortezomib-Induced Muscle Toxicity in Multiple Myeloma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 620-630.	0.9	19
28	Co-delivery of indoleamine 2,3-dioxygenase prevents loss of expression of an antigenic transgene in dystrophic mouse muscles. <i>Gene Therapy</i> , 2017, 24, 113-119.	2.3	3
29	The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma. <i>Nature Communications</i> , 2017, 8, 619.	5.8	77
30	Selection of an optimal promoter for gene transfer in normal B cells. <i>Molecular Medicine Reports</i> , 2017, 16, 3041-3048.	1.1	6
31	Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy. <i>Annals of Oncology</i> , 2017, 28, v418-v419.	0.6	2
32	Abstract 3975: Ovarian cancer cells release arginase-1-containing exosomes to suppress antitumor immune response. , 2017, , .		0
33	MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. <i>PLoS ONE</i> , 2016, 11, e0155893.	1.1	26
34	Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma. <i>Oncotarget</i> , 2016, 7, 1717-1731.	0.8	48
35	Abstract 4501: Immunophenotypic identities of clinical samples have the potential to correlate with overall survival in cytogenetically normal AML patients. , 2016, , .		0
36	Abstract 5347: SK053, a small molecule inhibitor of enzymes involved in allosteric disulfide bonds formation, shows potent anti-leukemic effects and induces differentiation of human AML cells. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
37	MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. <i>Blood</i> , 2015, 126, 4917-4917.	0.6	0
38	Statins impair glucose uptake in human cells. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000017.	1.2	37
39	Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model. <i>Translational Oncology</i> , 2014, 7, 570-579.	1.7	17
40	Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. <i>Breast Cancer Research</i> , 2014, 16, R79.	2.2	52
41	Adenanthin targets proteins involved in the regulation of disulphide bonds. <i>Biochemical Pharmacology</i> , 2014, 89, 210-216.	2.0	36
42	Peroxiredoxins-1 and 2 Affect Proliferation and Survival of Lymphoma Cells. <i>Blood</i> , 2014, 124, 1693-1693.	0.6	1
43	SK053, an Inhibitor of Enzymes Involved in Allosteric Disulfide Bonds Formation, Targets Expression of Histone Genes and Induces Differentiation of Human AML Cell. <i>Blood</i> , 2014, 124, 3503-3503.	0.6	0
44	GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. <i>Cell Death and Disease</i> , 2013, 4, e741-e741.	2.7	52
45	SK053 An Inhibitor Of Enzymes Involved In Allosteric Disulfide Bonds Formation Induces Differentiation Of Human AML Cells. <i>Blood</i> , 2013, 122, 4215-4215.	0.6	0
46	Statins Impair Glucose Uptake in Tumor Cells. <i>Neoplasia</i> , 2012, 14, 311-323.	2.3	37
47	Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity. <i>Journal of Biological Chemistry</i> , 2012, 287, 31983-31993.	1.6	19
48	Approaches to improve photodynamic therapy of cancer. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 208.	3.0	44
49	Antitumor effects of the combination of cholesterol reducing drugs. <i>Oncology Reports</i> , 2011, 26, 169-76.	1.2	7
50	Optimization of activation requirements of immature mouse dendritic JAWSII cells for in vivo application. <i>Oncology Reports</i> , 2011, 25, 831-40.	1.2	11
51	Photodynamic therapy of cancer: An update. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 250-281.	157.7	3,902
52	PDT-induced inflammatory and host responses. <i>Photochemical and Photobiological Sciences</i> , 2011, 10, 653-663.	1.6	76
53	Sorafenib Affects Membrane Complement Inhibitors and Improves Antitumor Activity of Rituximab,. <i>Blood</i> , 2011, 118, 3723-3723.	0.6	0
54	Prenyl Transferases Are Involved in the Regulation of CD20 Levels and Influence Anti-CD20 Monoclonal Antibody-Mediated Activation of Complement-Dependent Cytotoxicity,. <i>Blood</i> , 2011, 118, 3722-3722.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Src Family Tyrosine Kinases Are Involved in the Transcriptional Regulation of CD20 Levels. <i>Blood</i> , 2011, 118, 1661-1661.	0.6	0
56	Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity. <i>Blood</i> , 2010, 115, 3745-3755.	0.6	40
57	Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2010, 15, 1050-1071.	2.2	253
58	Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1805, 53-71.	3.3	292
59	Proteolytic pathways involved in modulation of CD20 levels. <i>Autophagy</i> , 2010, 6, 810-812.	4.3	4
60	Studies of the Synthesis of All Stereoisomers of MG-132 Proteasome Inhibitors in the Tumor Targeting Approach. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1509-1518.	2.9	38
61	Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib. <i>American Journal of Pathology</i> , 2010, 176, 2658-2668.	1.9	115
62	Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. <i>Cancer Letters</i> , 2010, 288, 57-67.	3.2	34
63	Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein Response. <i>Cancer Research</i> , 2009, 69, 4235-4243.	0.4	96
64	Improvement of anti-tumor activity of photodynamic therapy through inhibition of cytoprotective mechanism in tumor cells. , 2009, , .		1
65	The possible role of factor H in colon cancer resistance to complement attack. <i>International Journal of Cancer</i> , 2008, 122, 2030-2037.	2.3	44
66	Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice. <i>BMC Cancer</i> , 2008, 8, 197.	1.1	59
67	Sarcolemmal Ca ²⁺ -ATPase ability to transport Ca ²⁺ gradually diminishes after myocardial infarction in the rat. <i>Cardiovascular Research</i> , 2008, 81, 546-554.	1.8	21
68	Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20. <i>PLoS Medicine</i> , 2008, 5, e64.	3.9	115
69	Ciglitazone, an agonist of peroxisome proliferator-activated receptor γ , exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin. <i>International Journal of Oncology</i> , 2008, , .	1.4	2
70	Ciglitazone, an agonist of peroxisome proliferator-activated receptor gamma, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin. <i>International Journal of Oncology</i> , 2008, 32, 249-55.	1.4	3
71	Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome. <i>Acta Biochimica Polonica</i> , 2008, 55, 75-84.	0.3	3
72	Erythropoietin reduces cisplatin-induced neurotoxicity without impairment of cytotoxic effects against tumor cells. <i>International Journal of Oncology</i> , 2007, 31, 1547-52.	1.4	3

#	ARTICLE	IF	CITATIONS
73	Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. <i>International Journal of Oncology</i> , 2007, , .	1.4	6
74	A novel function of VCP (valosin-containing protein; p97) in the control of N-glycosylation of proteins in the endoplasmic reticulum. <i>Archives of Biochemistry and Biophysics</i> , 2007, 462, 62-73.	1.4	15
75	TNF potentiates anticancer activity of bortezomib (Velcade®) through reduced expression of proteasome subunits and dysregulation of unfolded protein response. <i>International Journal of Cancer</i> , 2007, 121, 431-441.	2.3	26
76	Statins Impair Antitumor Effects of CD20 mAb by Inducing Conformational Changes of CD20.. <i>Blood</i> , 2007, 110, 2341-2341.	0.6	0
77	Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. <i>International Journal of Oncology</i> , 2007, 30, 1413-25.	1.4	8
78	Destabilization of the VCP-Ufd1-Npl4 complex is associated with decreased levels of ERAD substrates. <i>Experimental Cell Research</i> , 2006, 312, 2921-2932.	1.2	36
79	Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. <i>Oncogene</i> , 2006, 25, 3365-3374.	2.6	163
80	Valosin-containing Protein (p97) Is a Regulator of Endoplasmic Reticulum Stress and of the Degradation of N-End Rule and Ubiquitin-Fusion Degradation Pathway Substrates in Mammalian Cells. <i>Molecular Biology of the Cell</i> , 2006, 17, 4606-4618.	0.9	165
81	The influence of photodynamic therapy on the immune response. <i>Photodiagnosis and Photodynamic Therapy</i> , 2005, 2, 283-298.	1.3	83
82	Direct tumor damage mechanisms of photodynamic therapy.. <i>Acta Biochimica Polonica</i> , 2005, 52, 339-352.	0.3	222
83	Direct tumor damage mechanisms of photodynamic therapy. <i>Acta Biochimica Polonica</i> , 2005, 52, 339-52.	0.3	63
84	CpG Immunostimulatory Oligodeoxynucleotide 1826 Enhances Antitumor Effect of Interleukin 12 Gene-Modified Tumor Vaccine in a Melanoma Model in Mice. <i>Clinical Cancer Research</i> , 2004, 10, 4165-4175.	3.2	35
85	Corvastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. <i>International Journal of Oncology</i> , 2004, 24, 1149.	1.4	17
86	AAF-cmk sensitizes tumor cells to trail-mediated apoptosis. <i>Leukemia Research</i> , 2004, 28, 53-61.	0.4	4
87	Effective Photoimmunotherapy of Murine Colon Carcinoma Induced by the Combination of Photodynamic Therapy and Dendritic Cells. <i>Clinical Cancer Research</i> , 2004, 10, 4498-4508.	3.2	142
88	Corvastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. <i>International Journal of Oncology</i> , 2004, 24, 1149-57.	1.4	20
89	Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. <i>Oncology Reports</i> , 2004, 12, 1371-5.	1.2	11
90	Antitumor Effects of Photodynamic Therapy Are Potentiated by 2-Methoxyestradiol. <i>Journal of Biological Chemistry</i> , 2003, 278, 407-414.	1.6	113

#	ARTICLE	IF	CITATIONS
91	Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. <i>Clinical Cancer Research</i> , 2003, 9, 5417-22.	3.2	46
92	Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. <i>Oncology Reports</i> , 2002, 9, 199.	1.2	0
93	Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. <i>International Journal of Cancer</i> , 2002, 97, 746-750.	2.3	16
94	Stimulation of TNF- β production by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) - a novel immunomodulator with potential application in tumour immunotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 213-222.	1.1	4
95	Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. <i>Oncology Reports</i> , 2002, 9, 199-203.	1.2	2
96	Antitumor activity of tributyrin in murine melanoma model. <i>Cancer Letters</i> , 2001, 164, 143-148.	3.2	16
97	In vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor. <i>FEBS Letters</i> , 2001, 503, 219-220.	1.3	13
98	Butyric acid enhances in vivo expression of hTNF-alpha in transduced melanoma cell line. <i>Anticancer Research</i> , 2001, 21, 4001-4.	0.5	1
99	Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. <i>Oncology Reports</i> , 0, , .	1.2	1
100	Rpt6. <i>The AFCS-nature Molecule Pages</i> , 0, , .	0.2	0
101	Rpt4. <i>The AFCS-nature Molecule Pages</i> , 0, , .	0.2	0
102	Rpt3. <i>The AFCS-nature Molecule Pages</i> , 0, , .	0.2	0